Michael Nofi - 10 Nov 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
10 Nov 2026, 17:21:39 UTC
Prior SEC filing
17 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John R. Moore, Attorney-in-Fact for Michael Nofi
Filing notes and source

Key filing fact

Michael Nofi filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 10 Nov 2026.

Key facts

  • This page summarizes Michael Nofi's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 10 Nov 2026, 17:21.

Change

  • Previous filing in this sequence was filed on 17 Aug 2026.
  • Current net transaction value: -$201,787.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001705477 Primary reporting owner

Nofi Michael

Relationship
Chief Financial Officer
Address
1715 38TH STREET, BOULDER
Signature
/s/ John R. Moore, Attorney-in-Fact for Michael Nofi
Signature date
10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EWTX transaction

Common Stock

Options Exercise

Transaction value
Shares
+10,937
Change %
Price
$0.000000*
Shares after
10,937
Date
10 Nov 2026
Ownership
Direct
EWTX transaction

Common Stock

Sale

Transaction value
-$201,787
Shares
-4,442
Change %
-41%
Price
$45.43
Shares after
6,495
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-10,937
Change %
-25%
Price
$0.000000*
Shares after
32,813
Date
10 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,937
Exercise price
$0.000000
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

Footnote F2

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .